Plus Therapeutics, Inc. (PSTV)

Nasdaq: PSTV · Surgical & Medical Instruments & Apparatus · Austin, TX · filing with the SEC since 2001

Full chart Alerts Compare

Grade2.9

◀ Past 1.3● Present 2.7▶ Future 4.7

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Plus Therapeutics, Inc.

Nine metrics read from its own filings, by tense

Headline grade

2.9/10

◀ Past1.330% of the headline

● Present2.740% of the headline

▶ Future4.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.3/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.5/10

Has it survived what it has been through?

15 warning events since 2017; the latest 2025-07-18.

weight 33% of this tense · 15th percentile among 121 sector filers · read for itself

From the record

Plus Therapeutics, Inc.'s filings since 2017 show 15 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 12 times, the latest 2025-06-06); an auditor change (8-K item 4.01, the latest 2025-07-18); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2025-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.3/10

What has it actually done, year after year?

-3% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 13th percentile among 105 sector filers · read for its customers

From the record

Plus Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $8 million in fiscal 2011 to $5 million in fiscal 2025, down 3% a year; it rose in 3 of 9 years; the deepest fall was 69% from fiscal 2012 to fiscal 2017; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-3.0%bottom 9% of its family
the share of years revenue rosebottom 6% of its family
the share of filed years with a profitbottom 23% of its family
the deepest fall from a revenue peak69.1%bottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.9/10

How has it treated the people who own it?

SI estimate 0.9/10, confidence 35 of 100 (one part).

weight 22% of this tense · 9th percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 9% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Plus Therapeutics, Inc.'s shareholder treatment is put at 0.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 9% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.7/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

1.0/10

Is it financially healthy right now?

ROE -560%: lost 560¢ per shareholder dollar. Leverage 76%: owes 76¢ per asset dollar.

weight 45% of this tense · 10th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Plus Therapeutics, Inc. lost about 560 cents for every dollar of shareholders' money. Leverage: it owed about 76 cents per dollar of assets, and net share issuance: its share count grew 910.3% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 20% of its family
return on equitybottom 6% of its family
the share count against the year beforebottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

2.5/10

How strong is its position in its industry?

bottom 24% of 109 in its family; net margin -429.4%.

weight 33% of this tense · 24th percentile among 109 sector filers · read for its customers

From the record

Plus Therapeutics, Inc.'s standing among 109 graded names in its industry family: revenue of $5 million in fiscal 2025 ranks in the bottom 18% by size; a net margin of -429.4% ranks in the bottom 15%; revenue growth of 8.6% a year over the last 3 filed years ranks in the bottom 40% (its annual reports).

What it rests on

revenue against the family$5.2Mbottom 18% of its family
net margin-429.4%bottom 15% of its family
three-year revenue growth8.6%bottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

6.5/10

What are the people in charge doing?

top 35% of 91 in its family for leadership; chief executive since 2014.

weight 22% of this tense · 65th percentile among 91 sector filers · read for its shareholders

From the record

Plus Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hedrick, Marc H (Chief Executive Officer, as filed), filing under that title since 2014-04-15, 12.6 years (top 12% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 6.6 years (top 27%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 9 peoplebottom 35% of its family
the median years the people in charge have filed6.6 yearstop 27% of its family
the chief executive's years on the record12.6 yearstop 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.7/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.7/10

How much room does it have to grow?

top 43% of 104 in its family for room to expand.

weight 45% of this tense · 57th percentile among 104 sector filers · read for itself

From the record

Plus Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 26.1% of its assets as net cash, top 31% of its family; cash from operations less capital spending is -399.8% of revenue (bottom 12%); research spending of 160.7% of revenue (top 11%) (its annual report).

What it rests on

cash less debt against assets26.1%top 31% of its family
cash from operations less capital spending against revenue-399.8%bottom 12% of its family
research spending against revenue160.7%top 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.5/10

What could actually drive growth from here?

bottom 45% of 105 in its family for growth drivers.

weight 33% of this tense · 45th percentile among 105 sector filers · read for its customers

From the record

Plus Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 8.6% a year over the last three filed years against -3% over all 10, speeding up (top 11% of its family); the newest year grew -10.5% (bottom 13%); research spending grew -4.8% a year (bottom 25%); capital spending grew 0% a year (top 48%) (its annual reports). Plus Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+11.6 points a yeartop 11% of its family
the newest year's revenue growth-10.5%bottom 13% of its family
three-year growth of research spending-4.8%bottom 25% of its family
three-year growth of capital spending0.0%top 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

3.3/10

Did its newest year beat what its own record pointed to?

bottom 33% of 88 in its family for expectations against reality.

weight 22% of this tense · 33rd percentile among 88 sector filers · read for its shareholders

From the record

Plus Therapeutics, Inc.'s newest year against its own record: revenue of $5 million in fiscal 2025 came in 19.8% below the $7 million its prior three years' pace pointed to (bottom 21% of its family); net income of $22 million against a prior three-year average of $16 million (bottom 19%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 41%) (its annual reports).

What it rests on

revenue against the prior three years' pace-19.8%bottom 21% of its family
net income against the prior three years' average-37%bottom 19% of its family
net margin against its prior average+16.4 pointstop 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PSTV · research, not advice